UHCs typical prior authorization requirements for Wegovy and Zepbound include: BMI documentation A documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea Comorbidity evidence Clinical records documenting the specific comorbidities that support the medical necessity of treatment Supervised weight management history Evidence of participation in a structured weight management program, which may include diet, exercise, and behavioral counseling, typically for 3 to 6 months prior to the request Prescriber qualifications The prescriber must be a physician, nurse practitioner, or physician assistant with appropriate prescribing authority UHC reviews prior authorizations against specific clinical policy bulletins
Lower-dose maintenancesometimes half the dose used for initial weight lossmay provide appetite benefits while reducing medication burden
Personalized microbiome interventions are becoming more practical as sequencing costs decrease
Reviews from real Noom users Choosing the right weight loss medication Choosing between Mounjaro and metformin for weight loss and diabetes management is a deeply personal decision, one that depends on your health needs, lifestyle, and goals
These impurities may result from synthetic errors, incomplete reactions, or chemical instability during processing
)
